Xlife sciences

Where innovation leads to success

HALF-YEAR REPORT 2026

HALF-YEAR REPORT 2026

Dear shareholders

The first half of 2026 was marked by operational progress, developments across the portfolio, and the continued expansion of our platforms. The NASDAQ listing of our portfolio company VERAXA Biotech demonstrates how academic innovation can be further developed and financed within our model and brought to international capital markets.

VERAXA Biotech: From Research to NASDAQ

With the completion of the business combination and the commencement of trading on the NASDAQ Capital Market under the ticker symbol «VRXA» on June 11, 2026, VERAXA Biotech reached another milestone. For Xlife Sciences, gaining access to international investors in the U.S. capital market was an important interim step in helping to provide VERAXA with the growth capital required for its ambitious development activities.

Shareholder approval: In March, VERAXA's shareholders approved the merger with 99.57% of the represented share capital.

Financing base: Ahead of the listing, VERAXA secured a senior secured convertible note of USD 27.5 million and an additional equity financing facility of up to USD 50 million.

Development focus: The financing base supports the continued advancement of the oncology pipeline, particularly the preclinical and clinical development of the proprietary BiTAC platforms.

The focus is now on the operational development of the pipeline and the implementation of industry partnerships for the technology platforms and products. VERAXA Biotech's market value should increase positively as a result of technological validation, the company's operational progress, and the targeted partnerships. For Xlife Sciences, VERAXA's technologies remain an important building block for the development of selected portfolio companies and their innovations.

Increased Visibility in the Capital Markets

Xlife Sciences itself has also further strengthened its positioning in the capital markets. Since February 2, 2026, the Company's shares have been traded in the main segment of the SIX Swiss Exchange.

In addition, ODDO BHF initiated research coverage of Xlife Sciences. The independent analysis of our business model as a bridge between academic research and industrial value creation increases transparency and contributes to broader awareness of our strategic development.

At the same time, Xlife Sciences continued its presence at specialist conferences, partnering events, and investor forums. The resulting discussions are intended to support the business development activities of the portfolio companies, expand contacts with potential industry and financing partners, and increase the portfolio's visibility in relevant markets.

Portfolio: Operational and Scientific Developments

Our project companies achieved further significant progress.

- **x-kidney diagnostics:** Strategic partner Quant Biomarkers received approximately CHF 1 million in non-dilutive innovation funding to further develop a biomarker platform for the early detection of chronic kidney disease.

- **saniva diagnostics:** The company successfully completed the second clinical study of the NeuroMex system for the early detection of neurodegenerative diseases. The focus is now on partnering with international medical technology companies.

- **Axenoll:** Together with an industry partner, the company is establishing the conditions for pre-series production of biomaterial-based applications and advancing preparations for a subsequent market launch.

- **FUSE-AI:** The successful recertification under ISO 13485 strengthens its positioning in the field of AI-based medical software solutions.

- **inflamed pharma:** The company made further progress with its proprietary formulation technology and is expanding its portfolio of innovative active ingredients for applications in health, nutrition, and healthy aging.

The 2025 Valuation Report published in May provides an assessment of the diversification and long-term development of the project portfolio. Following three years with CYLAD, the valuation was conducted for the first time by ValueTrust Financial Advisors Switzerland AG. As of December 31, 2025, a valuation range of CHF 563 million to CHF 712 million was determined. The valuation takes into account operational progress, current market conditions, and project-specific developments and provides a basis for the continued development and commercialization of our investments.

2026 Annual General Meeting

At the Annual General Meeting held on June 26, 2026, shareholders approved all proposals submitted by the Board of Directors. During the event, the Company also provided information on the development of the portfolio and the strategic priorities for the second half of the year.

Patent Portfolio as a Basis for Partnerships

Over the past six months, four additional patents have been granted in key international markets. Xlife currently holds a patent portfolio of 416 patents, of which 216 have already been granted. Recent significant achievements include patent grants for Axenoll, alytas therapeutics, and saniva diagnostics in relevant markets.

These patent grants strengthen the technological and commercial positions of the respective investments. Intellectual property rights provide an important basis for technology transfers, licensing arrangements, and commercial partnerships.

Financial Performance in H1 2026

From the provision of services to our project companies, we generated revenue of CHF 476,234.– in the first half of 2026, as of June 30, 2026, compared with CHF 354,321.– in the prior-year period. Basic earnings per share amounted to CHF -29.08, compared with CHF -0.53 in the prior-year period. Total assets amounted to CHF 346,753,230.–, compared with CHF 536.3 million in the prior-year period. Equity amounted to CHF 206,322,604.–, compared with CHF 391.9 million in the prior-year period. Cash and cash equivalents amounted to CHF 595,485.– as of the end of June 2026, compared with CHF 51,553.– as of the end of June 2025.

To safeguard the Company's financial flexibility, the founders have once again agreed to support the Company. In this context, the terms of the existing convertible loans were extended until mid-2029.

Outlook for H2 2026: Building on Success and Scaling Platforms

For the second half of 2026, our focus is on consistently translating the progress achieved into the next phase of development. This includes, in particular:

Further advancing VERAXA's value development: Supporting its continued strategic and operational progress as a publicly traded biotechnology company and the implementation of industry partnerships for its four technology platforms and pipeline.

Advancing portfolio projects: Focusing the development of scientifically compelling projects along clearly defined value creation and commercialization pathways.

Partnering: saniva has successfully completed two clinical studies involving its NeuroMex screening device for the early detection of Alzheimer's disease. At the current stage, the focus is on partnering with international medical technology companies.

Expanding our international presence:
The collaboration with Grupo Landsteiner continues to develop in line with the shared objective of combining scientific innovation with industrial implementation capabilities. For Xlife Sciences, the partnership creates additional opportunities for the industrialization of selected projects, access to international markets, and the expansion of our network across the entire value chain. Bringing innovative projects together with established expertise in production, regulatory affairs, and commercialization underlines our ambition to support scientific developments not only through proof of concept but, wherever possible, through broad market launch.

Further developing the platform and infrastructure: As part of the continued expansion of its platform, Xlife Sciences is evaluating selected infrastructure projects that could facilitate additional development stages, from research through industrial implementation, within the Xlife network. This is intended to complement the range of services offered across the value chain in a targeted manner. Individual projects will only be named once the ongoing decision-making and award processes have been completed.

Sharpening the capital markets profile: Expanding transparent communication with shareholders, analysts, and institutional investors.

We approach these tasks with confidence and a clear view of the necessary next steps. The developments in the first half of the year demonstrate that our model connects scientific innovation and entrepreneurial execution with access to partners and capital markets.

Our Thanks to Our Shareholders

Dear Shareholders, we would like to thank you for your trust and support. Important strategic steps were implemented during the first half of 2026. Together, we are working to enable Xlife Sciences and its portfolio companies to advance medical innovations, expand partnerships, and access international markets.

Zurich, September 2026

David L. Deck
Chairman of the Board of Directors

Oliver R. Baumann
CEO

CONDENSED HALF-YEAR REPORT 2026 OF THE XLIFE SCIENCES GROUP

Condensed income statement for the first half of 2026

In CHF	Notes	01.01.2026 –30.06.2026 unaudited	01.01.2025 –30.06.2025 unaudited
Revenue	4.1	**476,234**	**354,321**
Purchased services		(81,965)	(168,314)
Gross profit		**394,269**	**186,007**
Other income		3,921	228,699
Personnel expenses	4.2	(834,946)	(905,499)
Administrative expenses	4.3	(917,705)	(943,550)
Depreciation, amortisation and impairment of property, plant and equipment and intangible assets		(7,993,779)	(7,996,420)
Operating result before finance expense		**(9,348,240)**	**(9,430,763)**
Finance costs		(334,036)	(251,682)
Finance income		52,852	2,711
Gain/loss on disposal of financial assets		(1,506,248)	
Change in fair value - losses	5.1	(164,614,003)	(6,421,209)
Change in fair value - gains	5.1	3,221,726	8,571,577
Share of profit/loss of equity-accounted investees		(344,584)	(674,218)
Loss before income tax		**(172,872,533)**	**(8,203,583)**
Income tax benefit		2,369,657	2,369,657
Net loss		**(170,502,876)**	**(5,833,926)**
Attributable to shareholders of the parent company		(167,729,617)	(3,050,488)
Attributable to non-controlling interests		(2,773,259)	(2,783,438)
Basic earnings per share (CHF)	6.1	(29.08)	(0.53)
Diluted earnings per share (CHF)	6.1	(29.08)	(0.53)

Condensed statement of comprehensive income for the first half of 2026

In CHF	01.01.2026 –30.06.2026 unaudited	01.01.2025 –30.06.2025 unaudited
Result after taxes	**(170,502,876)**	**(5,833,926)**
Currency translation differences	(135,614)	1,281,993
Total comprehensive income	**(170,638,490)**	**(4,551,933)**
Attributable to shareholders of the parent company	(167,865,231)	(1,768,495)
Attributable to non-controlling interests	(2,773,259)	(2,783,438)

Condensed balance sheet as at 30 June 2026

In CHF	Notes	30.06.2026 unaudited	31.12.2025 audited
ASSETS			
Cash and cash equivalents		595,485	404,408
Trade receivables		94,087	93,630
Other receivables		505,337	365,664
Inventories		29,293	29,258
Current securities		647,255	646,470
Prepayments and accrued income		26,817	13,747
Current assets		**1,898,275**	**1,553,177**
Financial assets (equity-accounted investments)	5.2	16,506,237	17,088,451
Financial assets (loans)		11,339,135	9,502,979
Financial assets (projects / fair value)	5.1	70,596,604	234,548,431
Intangible assets		245,724,385	253,684,287
Property, plant and equipment		688,595	739,239
Non-current assets		**344,854,955**	**515,563,387**
Total assets		**346,753,230**	**517,116,564**
LIABILITIES AND EQUITY			
Trade payables		473,789	340,740
Other payables		1,487,498	1,457,848
Current lease liabilities		114,324	114,324
Current interest-bearing liabilities		4,326,524	6,521,968
Accrued expenses and deferred income		6,441,917	6,494,753
Current liabilities		**12,844,051**	**14,929,631**
Other liabilities		517,659	571,908
Provisions		61,362	61,362
Convertible loans	5.4	29,880,115	29,749,163
Convertible bond	5.3	23,668,073	23,616,668
Deferred tax liabilities		73,459,366	75,829,023
Non-current liabilities		**127,586,575**	**129,828,124**
Liabilities		**140,430,626**	**144,757,756**
Share capital	5.5	5,767,572	5,767,572
Reserves and share premium		168,841,185	165,737,573
Treasury shares		(14,475)	(1,377,535)
Retained earnings		(51,328,406)	116,401,211
Non-controlling interests		83,056,728	85,829,987
Equity		**206,322,604**	**372,358,809**
Total assets		**346,753,230**	**517,116,564**

CONDENSED HALF-YEAR REPORT 2026 OF THE XLIFE SCIENCES GROUP

Condensed cash flow statement for the first half of 2026

In CHF	01.01.2026 –30.06.2026 unaudited	01.01.2025 –30.06.2025 unaudited
Cash flows from operating activities		
Net income (net loss)	(170,502,876)	(5,833,926)
Adjustments to net loss for non-cash expenses/income		
Depreciation and amortisation	7,993,779	7,996,420
Change in financial assets at fair value	161,392,277	(2,150,369)
Change in equity-accounted investments	344,584	674,218
Other non-cash transactions	(304,693)	(728,480)
Changes in operating assets and liabilities		
Increase/decrease in trade receivables	(456)	(951,845)
Increase/decrease in prepayments, accrued income and other receivables	(152,743)	65,413
Increase/decrease in trade payables	133,117	(105,537)
Increase/decrease in lease and other liabilities	(54,249)	373,767
Increase/decrease in accrued expenses, deferred income and provisions	(23,186)	(7,864)
Cash generated from operating activities	**(1,174,447)**	**(668,202)**
Interest received		
Interest paid	(107,138)	(135,414)
Taxes paid		
Net cash inflow/outflow from operating activities	**(1,281,585)**	**(803,617)**
Cash flows from investing activities		
Disposal of financial assets measured at fair value (projects)	1,053,302	
Payments for intangible assets		
Purchase of securities		(691,855)
Payments for financial assets measured at fair value (projects)		
Loans to related parties (projects)	(1,836,155)	(1,081,698)
Net cash inflow/outflow from investing activities	**(782,853)**	**(1,773,553)**
Cash flows from financing activities		
Proceeds from the issue of shares and sale of treasury shares	1,331,398	
Proceeds from loans received from related parties	978,567	4,084,145
Repayment of loans		(1,500,000)
Lease payments (rental obligations)	(54,450)	(54,450)
Net cash inflow/outflow from financing activities	**2,225,515**	**2,529,695**
Net increase in cash and cash equivalents	**191,077**	**(47,475)**
Cash and cash equivalents at beginning of period	404,408	99,028
Effects of exchange rate changes		
Cash and cash equivalents at end of period	**595,485**	**51,553**

Condensed Statement of changes in equity at 30 June 2026

In CHF	Issued capital	Capital reserve	Pension reserve	FX reserve	Reserves and share premium	Treasury shares	Retained earnings	Attributable to share-holders	Non-controlling interests	Equity
as at 31.12.2024 unaudited	**5,741,772**	**149,723,271**	**(27,251)**	**11,873,803**	**161,569,823**		**137,948,523**	**305,260,118**	**91,262,393**	**396,522,511**
Profit/(loss) for the period							(3,050,488)	(3,050,488)	(2,783,438)	(5,833,926)
Currency effects				1,281,993	1,281,993			1,281,993	(1,472)	1,280,521
IFRS 2 – employee share participation programme		116,800			116,800			116,800		116,800
Equity effects of convertible bonds and con-vertible loans		188,787			118,787			118,787		118,787
as at 30.06.2025 unaudited	**5,741,772**	**149,651,284**	**(27,251)**	**13,155,796**	**162,779,829**		**134,898,036**	**303,419,636**	**88,477,484**	**391,897,120**
as at 31.12.2025 audited	**5,767,572**	**153,506,457**	**(35,789)**	**12,266,905**	**165,737,573**	**(1,377,535)**	**116,401,211**	**286,528,821**	**85,829,987**	**372,358,809**
Profit/(loss) for the period							(167,729,617)	(167,729,617)	(2,773,259)	(170,502,876)
Currency effects				(135,614)	(135,614)			(135,614)		(135,614)
IFRS 2 – employee share participation programme		96,663			96,663			96,663		96,663
Shareholder contribution through a debt assump-tion (see 5,7)		3,174,225			3,174,225			3,174,225		3,174,225
Result from transactions in treasury shares		(31,661)			(31,661)	1,363,060		1,331,399		1,331,399
Share capital increases in the first half										
as at 30.06.2026 unaudited	**5,767,572**	**156,745,683**	**(35,789)**	**12,131,291**	**168,841,185**	**(14,475)**	**(51,328,406)**	**123,265,876**	**83,056,728**	**206,322,604**

Notes to the condensed half-year report as of 30 June 2026

1. GENERAL INFORMATION

These interim financial statements do not contain all of the disclosures normally included in annual financial statements. Accordingly, this report should be read in conjunction with the annual financial statements for the year ended 31 December 2025 and all public announcements made by Xlife Sciences AG during the interim reporting period. The unaudited condensed consolidated interim financial statements for the period from 1 January to 30 June 2026 have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting (IAS 34). The accounting policies and measurement principles applied in preparing these condensed consolidated interim financial statements are consistent with those applied in preparing the consolidated financial statements for the 2025 financial year.

Xlife Sciences AG is a Swiss company focused on enhancing the value of promising technologies in the life sciences sector. The Company aims to bridge the gap between research and development and healthcare markets, supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

The Company's operations essentially comprise contributed and acquired projects, each of which is measured at fair value, except for projects in which an interest of more than 20% is held. Such interests are accounted for using the equity method, while entities controlled by the Company are consolidated.

Unless otherwise stated, amounts in the consolidated interim financial statements are presented in Swiss francs (CHF). Both individual amounts and totals are shown using the values with the smallest rounding differences. Consequently, minor differences may arise when adding the individual amounts presented to the totals reported.

2. ESTIMATION UNCERTAINTIES AND JUDGEMENTS

In applying the Group accounting policies and measurement principles presented, management must exercise judgement and make estimates and assumptions regarding the carrying amounts of assets and liabilities that cannot readily be determined from other sources. The estimates and underlying assumptions are based on past experience and other factors considered relevant. Actual amounts may differ from these estimates.

The assumptions underlying the estimates are reviewed regularly. Changes in estimates are recognised in the period in which the estimate is revised if the change affects only that period. If the changes affect both the current and future reporting periods, they are recognised in the current and future periods accordingly.

The most significant judgements made by management in applying the Company's accounting policies and measurement principles, together with the principal effects of those judgements on the amounts recognised in the consolidated financial statements, are set out below. The key forward-looking assumptions and other major sources of estimation uncertainty at the end of the reporting period that may give rise to a significant risk of a material adjustment to the carrying amounts of assets and liabilities within the next financial year are also disclosed.

In our assessment, the assumptions underlying the fair value measurement of the projects (carrying amount CHF 70,596,604) are subject to material estimation uncertainty concerning the development and market launch timelines and the expenditure required. The Company has made assumptions regarding market entry for its projects. The development and market launch of the specific applications forming the basis of the project valuations have been estimated by the Company. The valuation of the projects depends on whether the assumptions made regarding market launch can be achieved. For each project, the Company estimates the probability of success at every stage of development. The overall probability of successful market entry changes depending on the actual progress of a phase. Estimates for each phase are reviewed regularly, generally annually unless significant events occur. Based on a sensitivity analysis, the Company assesses the impairment risk of each project arising from possible delays in market entry or changes in the probability of success.

The successful execution of the projects and the related realisation of the developments will continue to require significant funding. At least until the first projects are realised, this funding must be secured through further capital measures or project disposals. Whether the recognised fair value could be achieved in a forced sale at the projects' current stage of development depends on market conditions.

The measurement of intangible assets, particularly intellectual property rights (carrying amount CHF 245,724,385), is based on assumptions which, in our assessment, are subject to material estimation uncertainty concerning their expected use in development and market launch and the related expenditure required. The Company has estimated the necessary parameters; however, the valuation depends on whether the assumptions made can be achieved. The estimates are reviewed regularly, generally annually unless significant events occur.

3. SIGNIFICANT ACCOUNTING POLICIES

3.1 Information on Subsidiaries

Name of the subsidiary	Main business	Registered office	Voting rights and capital share 30.06.2026	Voting rights and capital share 31.12.2025
Fully Consolidated Subsidiaries				
alytas therapeutics GmbH	Development of an immunotherapy based on an antibody targeting obesity and senescence	Jena	51%	51%
Inventum Genetics GmbH	Development and manufacture of medical and biotechnology products	Mainz	100%	100%
inflamed pharma GmbH	Manufacture and development of chemical and pharmaceutical substances	Jena	70%	75%
clyxop devices GmbH	Development of biocellulose tubes for use in injuries to hollow organs		merged	merged
Firstgene Therapeutics GmbH	Development of materials and processes for immunisation and therapies		merged	merged
Firstgene Life Sciences GmbH	Innovative gene therapy approaches for treating rare and common diseases	Mainz	70%	70%
x-nuclear diagnostics GmbH	Diagnostic methods using radioactive material	Erfurt	100%	100%
x-kidney diagnostics GmbH	Medical technology for diseases of the kidney and other internal organs	Erfurt	100%	100%
xprot GmbH	Therapeutic approach for lung cancer		merged	merged
Xsight Optics GmbH	Development of a technology platform for patient monitoring		merged	merged
XRNA Biotech GmbH	Research into different RNA molecules	Zurich	100%	100%
Xlife Sciences GmbH	Management company providing services to projects in the EU	Mainz	100%	100%
Xlife Sciences Innovation GmbH	Subholding company	Zurich	100%	100%
Xlife Sciences Abu Dhabi LLC	Subholding company	Abu Dhabi	100%	100%

3.2 Currency translation

Subsidiaries whose functional currency is not the Swiss franc are translated into the Group's presentation currency, the Swiss franc, using the modified closing-rate method. Assets and liabilities are translated at the closing rate. Income statement items are translated at the average rate. Equity components are translated at historical rates at the dates on which they arose from the Group's perspective. Resulting exchange differences are recognised outside profit or loss in other comprehensive income. Cumulative currency translation differences recognised in equity are reclassified to profit or loss when a Group entity leaves the scope of consolidation.

30.06.2025	CHF/EUR
0.95023	Average rate for the period (translation of income and expenses)
0.94551	Closing rate for the period (translation of assets and liabilities)

31.12.2025	CHF/EUR
0.93703	Annual average rate (translation of income and expenses)
0.93050	Year-end closing rate (translation of assets and liabilities)

30.06.2026	CHF/EUR
0.92982	Average rate for the period (translation of income and expenses)
0.93163	Closing rate for the period (translation of assets and liabilities)

4. NOTES TO THE CONSOLIDATED INCOME STATEMENT

4.1 Income from contracts with customers (revenue)

The breakdown of consolidated revenue from contracts with customers for the period, excluding income from financial investments, is as follows:

In CHF	01.01.2026 –30.06.2026	01.01.2025 –30.06.2025
Revenue from services	476,234	354,321
Total	**476,234**	**354,321**

Revenue is generated from services provided to the projects. Service revenue is recognised at a point in time.

4.2 Breakdown of personnel expenses

In CHF	01.01.2026 –30.06.2026	01.01.2025 –30.06.2025
Wages and salaries	665,787	758,350
Social security expenses	107,669	106,159
Pension expenses / employee benefits	24,656	18,792
Other personnel expenses	36,834	22,198
Total	**834,946**	**905,499**

NOTES TO THE CONDENSED HALF-YEAR REPORT AS OF 30 JUNE 2026

4.3 Administrative expenses

The breakdown of other operating expenses for the period is as follows:

In CHF	01.01.2026 –30.06.2026	01.01.2025 –30.06.2025
Rental expenses (parking spaces and short-term leases)	44,856	49,819
Maintenance and energy expenses	5,878	3,569
Vehicle and transport expenses	9,465	14,077
Duties and fees, insurance	47,686	6,889
Capital market expenses	16,829	11,798
Consulting expenses	222,700	284,593
Accounting and audit	249,981	311,793
Advertising and selling expenses	5,464	57,057
Travel and entertainment expenses	107,391	84,771
Administrative expenses	109,118	44,478
Other operating expenses	33,796	9,301
Capital taxes	64,541	65,405
Total	**917,705**	**943,550**

5. NOTES TO THE CONSOLIDATED BALANCE SHEET

5.1 Financial assets / projects at fair value

The carrying amounts of the projects at the reporting date are shown in the following table:

In CHF	30.06.2026	31.12.2025
Projects (with investments)	70,596,604	234,548,431

A number of factors have a material influence on the valuation, some of which are beyond management's control.

On initial recognition, financial assets (projects) are measured at fair value. Subsequently, they are measured at fair value through profit or loss.

Current observable market data are generally not available for unlisted financial assets / projects measured at fair value. Their valuation is based on the inputs used in the relevant valuation technique and is generally classified within Level 3 of the fair value hierarchy (see Note 2). Where a quoted market price in an active market is available for a financial asset, that price is used to determine fair value.

Quantitative overview and ranges

In CHF	Level	Valuation method	Significant inputs	WACC used at 30 June 2026	WACC used previously
VITRUVIA MEDICAL AG	1	Quoted market price			
Axenoll Life Sciences AG	3	DCF model	Cost of capital	18%	20%
saniva diagnostics GmbH	3	DCF model	Cost of capital	18%	20%
VERAXA Biotech AG	1	Quoted market price			
Baliopharm AG[1]	3	DCF model	Cost of capital	16%	16%

The sensitivities of the financial assets are substantially unchanged from 31 December 2025 and are set out in section 5.1 of the 2025 consolidated financial statements.

Forward-looking statements used for valuation purposes are based on current estimates and assumptions reflecting the information available at the present date. These forward-looking statements are subject to risks, estimates, assumptions, uncertainties and other factors whose occurrence or non-occurrence may cause actual results to differ materially from, or fall short of, the implied forecasts and may require the project values to be adjusted in subsequent financial statements. There is material uncertainty regarding the valuation of the projects based on forecasts and estimates of future revenue.

Development of financial assets / Projects at fair value

In CHF	Interest	Registered office	Fair value 31 Dec, 2025	WACC	Additions	Disposals	Change	Fair value 30 June 2026	WACC
VITRUVIA MEDICAL AG	5.5%	Switzerland	62,077				19,726	81,802	
Axenoll Life Sciences AG	14.0%	Switzerland	7,801,000	20%			2,078,000	9,879,000	18%
saniva diagnostics GmbH	19.0%	Germany	5,203,000	20%			1,124,000	6,327,000	18%
VERAXA Biotech AG	17.2%	Switzerland	202,550,558	20%		(2,559,550)	(164,614,003)	35,377,005	
Baliopharm AG[1]		Switzerland	18,931,797	16%				18,931,797	16%
Total			**234,548,431**			**(2,559,550)**	**(161,392,227)**	**70,596,604**	

[1]These are acquired royalties under a licence agreement without a corresponding direct equity interest in the company.

Development of the Investment in VERAXA Biotech AG

In June 2026, the business combination of VERAXA Biotech AG was completed and the company's shares were admitted to trading on NASDAQ. As part of the transaction, the previously held shares in VERAXA Biotech AG were converted into shares of the listed company. As at 30 June 2026, the Group held 23,029,967 shares in VERAXA Biotech AG. Until 31 December 2025, in the absence of an observable market price, the fair value of the investment was determined using a valuation model based primarily on unobservable inputs. As at 31 December 2025, the fair value was CHF 202.6 million and was classified within Level 3 of the fair value hierarchy.

Following the stock exchange listing, a quoted market price in an active market was available for the shares of VERAXA Biotech AG as at 30 June 2026. Fair value was therefore determined using the unadjusted quoted price of USD 1.88 per share and the closing USD/CHF exchange rate of 0.81709. This resulted in a fair value of the investment of CHF 35.4 million. As at 30 June 2026, the valuation is classified within Level 1 of the fair value hierarchy. In connection with the listing of the investment, the Company committed not to sell any shares during the following 12 months.

During the first half of 2026, shares with a previous carrying amount of CHF 2.6 million were sold. The previous carrying amount was approximately equal to the market valuation on the first trading day. However, as the VERAXA share price subsequently declined very sharply, the remeasurement of the investment resulted in a fair value loss of CHF 164.6 million.

Reconciliation of VERAXA Biotech AG

In CHF	Valuation of VERAXA Biotech AG
Balance at 31 December 2025 (Level 3)	202,550,558
Sales between 1 January 2026 and 10 June 2026	(2,559,550)
Reclassification to Level 1 (market price) upon initial listing on 10 June 2026	199,991,008
Gains/losses recognised in profit or loss	(164,614,003)
Balance at 30 June 2026	**35,377,005**

5.2 Financial assets accounted for using the equity method

The carrying amounts of financial assets accounted for using the equity method at the reporting date are shown in the following table:

In CHF	Interest	Registered office	Equity-method carrying amount 31 Dec. 2025	Additions	Share of result	Disposals/ returns	FX effects	Equity-method carrying amount 30 June 2026
FUSE-AI GmbH	43.9%	Germany	1,501,151		(181,257)	(201,652)	(4,967)	1,113,276
palleos healthcare GmbH	50.0%	Germany	(52,168)		(95,642)			(147,810)
xarma life sciences GmbH	46.2%	Germany	20,611		(4,710)		(1,419)	14,482
QUADIRA BIOSCIENCES AG	50.0%	Switzerland	55,591					55,591
Lysatpharma GmbH	25.2%	Germany	15,614,546		(31,471)		18,901	15,601,976
Ix Therapeutics GmbH	50.0%	Germany	(723)				(13,963)	(14,685)
novaxomx GmbH	40.0%	Germany	(50,557)		(31,504)		(34,531)	(116,592)
Total			**17,088,451**		**(344,584)**	**(201,652)**	**(35,979)**	**16,506,237**

5.3 Convertible bond

The convertible bond developed as follows:

In CHF	30.06.2026	31.12.2025
Liability at beginning of period (1 January 2026 and 1 January 2025, respectively)	24,141,000	24,786,000
Conversions		645,000
Liability at end of period (30 June 2026 and 31 December 2025, respectively)	24,141,000	24,141,000
Equity effect	**(472,927)**	**(524,332)**
Carrying amount of the convertible bond	23,668,073	23,616,668
Of which due to related parties at period end	22,307,000	23,557,000
Interest rate	0.25%	0.25%
Final maturity	30.6.2029	30.6.2029
Conversion right at any time until 31 May 2029 at the conversion price	25.0 CHF/share	25.0 CHF/share

5.4 Convertible loan

The convertible loans developed as follows:

In CHF	30.06.2026	31.12.2025
Liability at beginning of period (1 January 2026 and 1 January 2025, respectively)	30,173,175	30,173,175
Conversions		
Liability at end of period (30 June 2026 and 31 December 2025, respectively)	30,173,175	30,173,175
Equity effect	**(293,060)**	**(424,012)**
Carrying amount of the convertible loans	29,880,115	29,749,163
Interest rate	0.25%	0.25%
Final maturity	31.5.2029	31.5.2029
Conversion right from 1 February 2023 at the earliest until 31 May 2029 at the conversion price	46.2 CHF/share	46.2 CHF/share

The convertible loan agreements were entered into exclusively with related parties.

5.5 Issued capital

In CHF	Number of Shares	Share Capital
Balance at 31 December 2024	**5,741,772**	**5,741,772**
Changes in the previous year	25,800	25,800
Balance at 31 December 2025	**5,767,572**	**5,767,572**
Changes in the reporting period		
Balance at 30 June 2026	**5,767,572**	**5,767,572**

The shares have a nominal value of CHF 1.00 each, carry one voting right per share and are entitled to dividends.

5.6 Treasury shares

In CHF	Number of shares	Transaction prices	Treasury shares in equity
Balance at 31 December 2024	286		
Sales in 2025	(155,000)	(3,509,054)	
Other changes			
Purchases and share loans	220,000	5,109,054	
Balance at 31 December 2025	**65,286**		**1,377,535**
Sales in the reporting period	(63,000)	(1,331,399)	
Other changes	(1,600)		
Purchases and share loans			
Balance at 30 June 2026	**686**		**14,475**

5.7 Waiver by a shareholder – Capital contribution

In CHF	01.01.–30.06.2026	01.01.–30.06.2025
Assumption of a liability by a shareholder for the benefit of Xlife Sciences AG	3,174,225	

A shareholder agreed to assume a liability of the Company without consideration, which was recognised as a capital contribution to the Company.

6. OTHER NOTES

6.1 Earnings per share

a) Basic earnings per share

In CHF per share	1. Semester 2026	1. Semester 2025
Basic earnings per share	(29.08)	(0.53)

The earnings and weighted average number of ordinary shares used in calculating basic earnings per share are set out below:

Result attributable to shareholders of the parent company	(167,729,617)	(3,050,488)
Weighted average number of ordinary shares used to calculate basic earnings per share	5,767,572	5,741,772

b) Diluted earnings per share

In CHF per share	Semester 1 2026	Semester 1 2025
Diluted earnings per share	(29.08)	(0.53)

The earnings and weighted average number of ordinary shares used in calculating diluted earnings per share are set out below:

Result attributable to shareholders of the parent company	(167,729,617)	(3,050,488)
Interest expense on convertible bonds, net of tax	82,490	83,469
Profit attributable to shareholders (diluted)	(167,647,127)	(2,967,019)
Weighted average number of ordinary shares (basic)	5,767,572	5,741,772
Effect of conversion of the convertible loans	1,604,902	1,630,702
Weighted average number of ordinary shares (diluted)	7,372,474	7,372,474

6.2 Business segments

As described below, the Xlife Sciences Group has four strategic focus areas that constitute its reportable segments. The Board of Directors regularly assesses these strategic areas, which have been formed based on similarities in products and services. All projects are allocated to these reportable segments. Xlife Sciences GmbH, Xlife Sciences Innovation GmbH and Xlife Sciences Abu Dhabi LLC are not allocated to a segment because they are internal service companies.

Technology Platforms
inflamed pharma GmbH, Jena, Germany
Inventum Genetics GmbH, Mainz, Germany
palleos healthcare GmbH, Wiesbaden, Germany
VERAXA Biotech AG, Zurich, Switzerland

Biotechnologies / Therapies
alytas therapeutics GmbH, Jena, Germany
Baliopharm AG, Reinach, Switzerland
Firstgene Life Sciences GmbH, Mainz, Germany
Ix Therapeutics GmbH, Hamburg, Germany
Lysatpharma GmbH, Eisenberg, Germany
QUADIRA BIOSCIENCES AG, Solothurn, Switzerland
xarma life sciences GmbH, Mainz, Germany
XRNA Biotech GmbH, Zurich, Switzerland

Medical Technology
Axenoll Life Sciences AG, Zurich, Switzerland
novaxomx GmbH, Frankfurt am Main, Germany
saniva diagnostics GmbH, Erfurt, Germany
VITRUVIA MEDICAL AG, Anglikon, Switzerland
x-kidney diagnostics GmbH, Erfurt, Germany
x-nuclear diagnostics GmbH, Erfurt, Germany

Artificial Intelligence / Digital Medicine
FUSE-AI GmbH, Hamburg, Germany

Technology Platforms
The Technology Platforms focus, independently of indication, on identifying new treatment options and continuously advancing technologies. They also serve as platforms for internal and external projects.

Biotechnologies / Therapies
The project companies in the Biotechnologies / Therapies segment focus on developing novel treatment options in specific therapeutic areas.

Medical Technology
The project companies in the Medical Technology segment develop innovative methods for diagnosing diseases and monitoring patients.

Artificial Intelligence / Digital Medicine
The Artificial Intelligence / Digital Medicine segment applies AI to improve diagnostic methods and processes in biotechnology.

In CHF	Technology Platforms	Biotechnologies / Therapies	Medical Technology	AI / Digital Medicine	Unallocated	Consolidated
First semester 2025						
External revenue	55,769				298,552	354,321
Intersegment revenue						
Total revenue	55,769				298,552	354,321
Segment profit (loss) before tax	2,861,833	(8,021,585)	(1,077,822)	(316,623)	(1,649,386)	(8,203,583)
Including: share of profit and loss of equity-accounted investees	(279,303)	(78,292)		(316,623)		(674,218)
Assets	197,894,148	295,475,490	19,439,701	997,361	22,450,617	536,257,317
Financial assets accounted for using the equity method	61,705	15,537,540	(50,557)	997,360		16,546,048
Liabilities	(193,909)	(78,212,792)	(23,836)		(65,929,659)	(144,360,196)
First semester 2026						
External revenue	71,234				405,000	476,234
Intersegment revenue						
Total revenue	71,234				405,000	476,234
Segment profit (loss) before tax	(164,836,583)	(7,987,596)	3,173,953	(181,257)	(3,041,050)	(172,872,533)
Including: share of profit and loss of equity-accounted investees	(95,642)	(36,181)	(31,504)	(181,257)		(344,584)
Assets	35,530,067	279,474,009	16,211,759	1,113,275	14,424,121	346,753,230
Financial assets accounted for using the equity method	(147,810)	15,657,364	(116,592)	1,113,275		16,506,237
Liabilities	(34,608)	(73,489,875)	(9,813)		(66,896,330)	(140,430,626)

6.3 Corporate bodies

Management	Oliver R. Baumann (CEO / Managing Director)
	Carl-Ferdinand von Halem (CFO / Member of the Executive Board)
	Dr Alexander Zink (CSO / Member of the Executive Board)
	Dr Frank Plöger (Managing Director USA)
	Christian Faber (Head of Legal & Compliance / Member of the Executive Board)
	Beat D. Kläui (Head of Tax & Accounting / Member of the Executive Board)
Board of Directors	David L. Deck (Chairman)
	Oliver R. Baumann (Member)
	Dr Norbert Windhab (Member)
	Désirée A. Dosch (Member)
	Mark S. Müller (Member)
Auditors	BDO AG, Baden

Zurich, 23.09.2026

Signed David L. Deck
Chairman of the Board of Directors

Phone +41 56 483 02 45
www.bdo.ch
baden@bdo.ch

BDO Ltd
Täfernstrasse 16
5405 Baden-Dättwil

INDEPENDENT AUDITOR'S REVIEW REPORT

To the Board of Directors of Xlife Sciences Ltd., Zurich

Review Report on the condensed consolidated interim financial statements

In accordance with your instructions, we have reviewed the accompanying condensed consolidated interim financial statements in accordance with IAS 34 of Xlife Sciences Ltd. for the period from 1st January 2026 to 30 June 2026.

These condensed consolidated interim financial statements in accordance with IAS 34 are the responsibility of the Board of Directors. Our responsibility is to issue a report on these condensed consolidated interim financial statements in accordance with IAS 34 based on our review.

We conducted our review in accordance with the Swiss Auditing Standard 910. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the condensed consolidated interim financial statements in accordance with IAS 34 are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements in accordance with IAS 34 do not give a true and fair view of the financial position, the results of operations and the cash flows in accordance with IAS 34.

Baden-Dättwil, 23 September 2026

BDO Ltd

Thomas Schmid
Swiss Certified Public Accountant

Jan Trautwein
Swiss Certified Public Accountant

This is a translation of the original German text. In case of discrepancies, the German version shall be decisive.

Enclosures
Condensed consolidated interim financial statements as of 30 June 2026

Important Dates

Annual Report 2026:
28 April 2027

Annual Shareholders Meeting 2027:
25 June 2027

Half-Year Report 2027:
24 September 2027

For roadshows and conferences,
please see
https://www.xlifesciences.ch/en/events

Contact

For Investors & Media:
Dr. Dennis Fink,
Senior Communications & Investor Relations Manager
dennis.fink@xlifesciences.ch

This is a translation of the original
German text. In case of discrepancies,
the German version shall be decisive.

Text: Xlife Sciences
Design: atelier MUY

Xlife sciences

Xlife Sciences AG
Talacker 35
CH-8001 Zurich
Switzerland

+41 (0) 44 385 84 60
www.xlifesciences.ch